ViewsML Raises $4.9M to Revolutionize Pathology with AI-Powered Virtual Biomarker Staining

ViewsML has announced the completion of an oversubscribed $4.9 million seed funding round led by Wittington Ventures to accelerate its AI-driven virtual staining technology. This capital infusion, supported by high-profile investors including the Mayo Clinic and Continuum Health Ventures, aims to transform traditional tissue analysis from a manual lab process into a high-speed software operation. By leveraging deep learning, the company is building the world’s first virtual biomarker library to provide spatial insights without the need for physical chemical stains.

The Future of AI in Pathology

The core of the platform utilizes sophisticated AI models to interpret routine pathology images, specifically standard hematoxylin and eosin slides. These models generate virtual immunohistochemistry results in minutes, bypassing the traditional days or weeks required for physical staining workflows. This breakthrough effectively eliminates a major diagnostic bottleneck in drug development while preserving valuable, scarce tissue samples that would otherwise be destroyed by repeated physical tests.

Clinical and Market Impact

With strategic backing from major healthcare and investment organizations, ViewsML is positioned to scale its computational layer across both research and clinical applications. The company claims its technology can offer up to 50 percent budget savings for laboratories by removing the need for physical reagents and manual labor. Current projects include deep learning models for Cyclin E1 biomarkers, which help researchers select patients for targeted clinical trials in gynecological malignancies.

Expanding the Virtual Library

The new funding will support the commercialization of the virtual library and expand partnerships with biopharma and diagnostic organizations globally. ViewsML plans to grow its engineering and scientific teams to advance the clinical validation of its virtual panels. The company is currently showcasing its latest validation studies at the American Association for Cancer Research Annual Meeting 2026 held at the San Diego Convention Center. CEO Kenneth To stated that this capital will enable the team to fast-track their vision of next-generation diagnostics. By virtualizing the diagnostic process, the startup intends to empower clinicians to analyze complex biological data at an unprecedented scale. This shift toward digital-first pathology represents a major milestone in the move toward accessible and efficient precision medicine.